<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta http-equiv="Content-Style-Type" content="text/css" />
  <meta name="generator" content="pandoc" />
  <title></title>
  <style type="text/css">code{white-space: pre;}</style>
</head>
<body>
<h3 id="mondo0016721"><a href="http://purl.obolibrary.org/obo/MONDO_0016721">MONDO:0016721</a></h3>
<p><strong>Label:</strong> pineal tumor of neuroepithelial tissue</p>
<p><strong>Subclasses:</strong> <a href="http://purl.obolibrary.org/obo/MONDO_0016722">MONDO:0016722</a> (pineoblastoma),</p>
<p><strong>Corr. equiv. classes:</strong> <a href="http://www.orpha.net/ORDO/Orphanet_251909">Orphanet:251909</a>,</p>
<p><strong>Class expressions from DL-Learner:</strong></p>
<ul>
<li><a href="http://purl.obolibrary.org/obo/HP_0030693">HP:0030693</a> (Supratentorial neoplasm) 100.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0030692">HP:0030692</a> (Brain neoplasm) 100.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010799">HP:0010799</a> (Pinealoma) 100.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0007987">HP:0007987</a> (Progressive visual field defects) and <a href="http://purl.obolibrary.org/obo/HP_0100012">HP:0100012</a> (Neoplasm of the eye) 100.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0007987">HP:0007987</a> (Progressive visual field defects) and <a href="http://purl.obolibrary.org/obo/HP_0030693">HP:0030693</a> (Supratentorial neoplasm) 100.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0007987">HP:0007987</a> (Progressive visual field defects) and <a href="http://purl.obolibrary.org/obo/HP_0030692">HP:0030692</a> (Brain neoplasm) 100.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0007987">HP:0007987</a> (Progressive visual field defects) and <a href="http://purl.obolibrary.org/obo/HP_0030063">HP:0030063</a> (Neuroepithelial neoplasm) 100.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0007987">HP:0007987</a> (Progressive visual field defects) and <a href="http://purl.obolibrary.org/obo/HP_0030061">HP:0030061</a> (Neuroectodermal neoplasm) 100.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0007987">HP:0007987</a> (Progressive visual field defects) and <a href="http://purl.obolibrary.org/obo/HP_0030060">HP:0030060</a> (Nervous tissue neoplasm) 100.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0007987">HP:0007987</a> (Progressive visual field defects) and <a href="http://purl.obolibrary.org/obo/HP_0012777">HP:0012777</a> (Retinal neoplasm) 100.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0007987">HP:0007987</a> (Progressive visual field defects) and <a href="http://purl.obolibrary.org/obo/HP_0011792">HP:0011792</a> (Neoplasm by histology) 100.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0007987">HP:0007987</a> (Progressive visual field defects) and <a href="http://purl.obolibrary.org/obo/HP_0010799">HP:0010799</a> (Pinealoma) 100.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0007987">HP:0007987</a> (Progressive visual field defects) and <a href="http://purl.obolibrary.org/obo/HP_0009919">HP:0009919</a> (Retinoblastoma) 100.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0007045">HP:0007045</a> (Midline brain calcifications) and <a href="http://purl.obolibrary.org/obo/HP_0007987">HP:0007987</a> (Progressive visual field defects) 100.00%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0002898">HP:0002898</a> (Embryonal neoplasm) and <a href="http://purl.obolibrary.org/obo/HP_0007987">HP:0007987</a> (Progressive visual field defects) 100.00%</li>
</ul>
</body>
</html>
